SCHEMBL14509190

SCHEMBL14509190

CC(=N)NCCCC(C)C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ ITGB3 P05106 5/20 0.33
▸ ITGA2B P08514 5/20 0.33
▸ PAOX Q6QHF9 2/20 0.33
▸ DPP7 Q9UHL4 2/20 0.33
▸ KISS1R Q969F8 1/20 0.33
▸ SPHK1 Q9NYA1 3/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ NPY4R P50391 2/20 0.30
▸ RRM1 P23921 1/20 0.30
▸ DPP4 P27487 1/20 0.30
▸ DPP8 Q6V1X1 1/20 0.30
▸ DPP9 Q86TI2 1/20 0.30
▸ NPY1R P25929 1/20 0.30
▸ NPY2R P49146 1/20 0.30
▸ NPY5R Q15761 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25477138 1.00 KDM4E (0.34) KDM4EMAPK1HIF1AITGB3ITGA2B
SCHEMBL13402408 0.87 ALOX15 (0.40) ITGB3ITGA2BDPP7MEN1KMT2A
SCHEMBL8297085 0.87 ALOX15 (0.40) ITGB3ITGA2BDPP7MEN1KMT2A
SCHEMBL17793248 0.87 ALOX15 (0.40) ITGB3ITGA2BDPP7MEN1KMT2A
SCHEMBL14509061 0.85 KISS1R (0.38) KDM4EMAPK1HIF1APAOXDPP7
SCHEMBL18233190 0.85 KISS1R (0.38) KDM4EMAPK1HIF1APAOXDPP7
SCHEMBL23106058 0.85 KDM4E (0.52) KDM4EMAPK1HIF1APAOXDPP7
SCHEMBL15030995 0.83 BLM (0.46) KDM4EMAPK1HIF1AITGB3ITGA2B
SCHEMBL18233928 0.83 BLM (0.46) KDM4EMAPK1HIF1AITGB3ITGA2B
SCHEMBL27405296 0.83 ITGB3 (0.31) KDM4EMAPK1HIF1AITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070105783-A1 Process for the manufacture of peptide facilitators of reverse cholesterol transport SIRCAR JAGADISH C 2007-05-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105783-A1 Process for the manufacture of peptide facilitators of reverse cholesterol transport CETP, NPC1L1, SLC10A1 KDM4E 4154/4885MAPK1 1802/4885HIF1A 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback